// App-Quantinova.ai

PB1356 : Immune Thrombocytopenia Treatment with Fostamatinib, a Spleen Tyrosine Kinase Inhibitor: Reducing the Risk of Thrombosis

Researchers

Presenter

  • N. Cooper

Principal Investigators

  • I. Altomare

  • Y. Kreychman

  • V. Markovtsov

  • E. Masuda

  • S. Tong

  • J. Bussel

Medical Centers

  • Imperial College Healthcare NHS Trust St Marys Hospital, London, United Kingdom

  • Duke University, Durham, North Carolina, United States

  • Rigel Pharmaceuticals, Inc., Dept. of Medical Affairs, South San Francisco, United States

  • Rigel Pharmaceuticals, Inc., Dept. of Medical Affairs, South San Francisco, United States

  • Rigel Pharmaceuticals, Inc., Dept. of Medical Affairs, South San Francisco, United States

  • Pediatrics, Weill Cornell Medical College, New York, New York, United States

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Fostamatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved